Država: Velika Britanija
Jezik: angleščina
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Escitalopram oxalate
Zentiva Pharma UK Ltd
N06AB10
Escitalopram oxalate
5mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04030300; GTIN: 5000283657187
2020 04 UK MAH address change 5 mg ZN2952 PACKAGE LEAFLET: INFORMATION FOR THE USER ESCITALOPRAM 5 MG FILM-COATED TABLETS Eight important things you need to know about Escitalopram Please read all of the leaflet. It includes a lot of additional important information about this medicine. • ESCITALOPRAM TREATS DEPRESSION. Like all medicines it can have unwanted effects. It is therefore important that you and your doctor weigh up the benefits of treatment against the possible unwanted effects, before starting treatment. • ESCITALOPRAM IS NOT FOR USE IN CHILDREN AND ADOLESCENTS UNDER 18. See section 2, Use in c _hildren _ _and adolescents under 18 years of age, _ inside this leaflet. • ESCITALOPRAM WON’T WORK STRAIGHT AWAY. Some people taking antidepressants feel worse before feeling better. Your doctor should ask to see you again a couple of weeks after you first start treatment. Tell your doctor if you haven’t started feeling better. See section 3, _How to take _ _escitalopram, _ inside this leaflet. • SOME PEOPLE WHO ARE DEPRESSED THINK OF HARMING OR KILLING THEMSELVES. If you start to feel worse, or think of harming or killing yourself, SEE YOUR DOCTOR OR GO TO A HOSPITAL STRAIGHT AWAY. See section 2 _Thoughts of suicide and worsening of your depression, _ inside this leaflet. • DON’T STOP TAKING ESCITALOPRAM WITHOUT TALKING TO YOUR DOCTOR. If you stop taking escitalopram suddenly or miss a dose, you may get withdrawal effects. See section 4, S _topping escitalopram, _ inside this leaflet. • IF YOU FEEL RESTLESS AND FEEL LIKE YOU CAN’T SIT OR STAND STILL, TELL YOUR DOCTOR. Increasing the dose of escitalopram may make these feelings worse. See section 5, _Possible side effects, _ inside this leaflet. • TAKING SOME OTHER MEDICINES WITH ESCITALOPRAM CAN CAUSE PROBLEMS. You may need to talk to your doctor. See section 2 _Other medicines and escitalopram, _ inside this leaflet. • IF YOU ARE PREGNANT OR PLANNING TO GET PREGNANT, talk to your doctor. See section 2 _Pregnancy, _ _breastfeeding and Preberite celoten dokument
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Escitalopram 5 mg film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 5 mg escitalopram (as escitalopram oxalate) Excipients with known effect Each Escitalopram 5 mg film-coated tablet contains maximum of 0.42 mg sodium. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM White to off-white, round, biconvex film-coated tablets. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment of major depressive episodes. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults Safety of daily doses above 20 mg has not been demonstrated. Escitalopram is administered as a single daily dose and may be taken with or without food. _Major depressive episodes _ Usual dosage is 10 mg once daily. Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily. Usually 2-4 weeks are necessary to obtain antidepressant response. After the symptoms resolve, treatment for at least 6 months is required for consolidation of the response. Elderly patients (> 65 years of age) Initial dosage is 5 mg once daily. Depending on individual patient response the dose may be increased to 10 mg daily (see section 5.2). Children and adolescents (< 18 years) Escitalopram should not be used in the treatment of children and adolescents under the age of 18 years (see section 4.4). Reduced renal function Dosage adjustment is not necessary in patients with mild or moderate renal impairment. Caution is advised in patients with severely reduced renal function (CL CR less than 30 ml/min) (see section 5.2). Reduced hepatic function An initial dose of 5 mg daily for the first two weeks of treatment is recommended in patients with mild or moderate hepatic impairment. Depending on individual patient response, the dose may be increased to 10 mg daily. Caution and extra careful dose titration is advised in patients with severely reduced hepatic function (see section 5.2). Poor metabolisers of CYP2C19 For pat Preberite celoten dokument